Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Heidi S. Taatjes‐Sommer"'
Autor:
David J. Schneider, Tristan Honda, Edward Feldmann, Adam de Havenon, Jose G. Romano, Raul G. Nogueira, Shyam Prabhakaran, Nishant K. Mishra, Charles B. Beaman, Jason Hinman, Christopher S. Commichau, Peter Callas, Naoki Kaneko, Jose M. Morales, Smit D. Patel, Latisha K. Sharma, Song Julia Kim, Heidi S. Taatjes‐Sommer, David S. Liebeskind
Publikováno v:
Stroke: Vascular and Interventional Neurology, Vol 2, Iss 3 (2022)
Background Platelet FcγRIIa amplifies platelet activation and, thus, increased expression identifies patients with increased platelet reactivity. Previous work has demonstrated that platelet FcγRIIa can identify patients at high and low risk of sub
Externí odkaz:
https://doaj.org/article/486a816d706641cba507699dfc90e25b
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/3a53b0c96cc947eb9d00924348d16e22
Autor:
Francesco Franchi, David J. Schneider, Jayne Prats, Weihong Fan, Fabiana Rollini, Latonya Been, Heidi S. Taatjes-Sommer, Deepak L. Bhatt, Efthymios N. Deliargyris, Dominick J. Angiolillo
Publikováno v:
Journal of Thrombosis and Thrombolysis. 54:373-381
Low dose enteric-coated aspirin (EC-ASA) is routinely used for secondary cardiovascular event prevention. However, absorption of EC tablets is poor, which can result in subtherapeutic antiplatelet effects. Phospholipid-aspirin liquid filled capsules
Publikováno v:
Journal of cardiovascular pharmacology. 78(2)
The combination of pharmaceutical lipid excipients with aspirin in a novel liquid oral formulation (Vazalore) limits gastrointestinal toxicity of aspirin. This study was performed to determine whether the lipid excipients influence the pharmacodynami
Autor:
Gregory L. Ehle, Sean R. McMahon, Heidi S. Taatjes-Sommer, Sean Meagher, David J. Schneider, Sreedivya Chava
Publikováno v:
The American journal of cardiology. 125(5)
Platelet expression of FcγRIIa was quantified after myocardial infarction (MI) and we found that patients with high platelet FcγRIIa expression (>11,000/platelet) had a fourfold greater risk of subsequent MI, stroke, and death. This analysis of the
Autor:
Kathleen E. Brummel-Ziedins, Sean Meagher, David J. Schneider, Sreedivya Chava, Sean R. McMahon, Heidi S. Taatjes-Sommer
Publikováno v:
Journal of thrombosis and thrombolysis. 48(1)
FcγRIIa amplifies platelet activation and greater platelet expression of FcγRIIa identifies patients at greater risk of subsequent cardiovascular events. Thus, platelet expression of FcγRIIa may be useful to guide therapy. Because platelet functio
Autor:
David J, Schneider, Sean R, McMahon, Sreedivya, Chava, Heidi S, Taatjes-Sommer, Sean, Meagher, Gregory L, Ehle, Kathleen E, Brummel-Ziedins
Publikováno v:
Journal of the American College of Cardiology. 72(2)
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 29:1138-1143
Objective—The purpose of this study was to identify factors that alter expression of FcγRIIa by megakaryocytes.Methods and Results—Effects of selected cytokines and growth factors on megakaryocyte expression of FcγRIIa were assessed with phorbo
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 29(7)
The purpose of this study was to identify factors that alter expression of FcgammaRIIa by megakaryocytes.Effects of selected cytokines and growth factors on megakaryocyte expression of FcgammaRIIa were assessed with phorbol 12-myristate 13-acetate (P